Cantor Fitzgerald Estimates DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLIFree Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Denali Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($3.15) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

DNLI has been the topic of several other research reports. William Blair upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. HC Wainwright decreased their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Robert W. Baird decreased their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. Wedbush decreased their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, Oppenheimer decreased their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Buy” and a consensus price target of $33.71.

Check Out Our Latest Research Report on DNLI

Denali Therapeutics Stock Performance

DNLI stock opened at $15.19 on Tuesday. The firm has a market cap of $2.21 billion, a PE ratio of -5.50 and a beta of 1.32. The firm’s fifty day moving average is $14.03 and its 200 day moving average is $17.99. Denali Therapeutics has a one year low of $10.57 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the prior year, the business posted ($0.68) EPS.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DNLI. KLP Kapitalforvaltning AS acquired a new stake in Denali Therapeutics during the fourth quarter worth about $532,000. Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics during the fourth quarter worth about $514,000. Vanguard Group Inc. increased its position in Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after purchasing an additional 843,996 shares during the last quarter. Norges Bank acquired a new stake in Denali Therapeutics during the fourth quarter worth about $21,717,000. Finally, Teacher Retirement System of Texas increased its position in Denali Therapeutics by 18.6% during the fourth quarter. Teacher Retirement System of Texas now owns 38,178 shares of the company’s stock worth $778,000 after purchasing an additional 5,987 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

See Also

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.